Anti-VEGF monoclonal antibody (specialist)
Bevacizumab
Brand names: Avastin
Adult dose
Dose: Per protocol — 5–15mg/kg IV q2–3w
Route: IV
Frequency: q2–3w
Clinical pearls
- Multiple NICE TAs (mCRC, ovarian, NSCLC, RCC, glioblastoma — variable funding)
- ESMO disease-specific guidelines
- Off-label intravitreal use for nAMD / DMO common globally; UK NHS uses ranibizumab/aflibercept
Contraindications
- Active bleeding
- Recent surgery (4-week washout)
- Severe hypertension
- Pregnancy
- Hypersensitivity
Side effects
- Hypertension
- Proteinuria / nephrotic syndrome
- GI perforation
- Wound healing impairment
- Haemorrhage
- VTE
- Posterior reversible encephalopathy syndrome (PRES)
- Heart failure
Interactions
- Sunitinib (combination — TMA)
Monitoring
- BP
- Urinalysis (proteinuria)
- Wound healing
- Bleeding/perforation symptoms
Reference: BNF; multiple NICE TAs; ESMO; SmPC; https://bnf.nice.org.uk/drugs/bevacizumab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina